Pharmaceutical marketing through financial incentivisation to general practitioners (GPs) is a poorly studied health system problem in Pakistan. Pharmaceutical incentivisation is seen to be distorting GPs prescribing behaviour that can compromise the health and well-being of patients. We draw on a conceptual framework outlined in the ecological system theory to identify multiple factors linked with pharmaceutical incentivisation to GPs in Pakistan. We conducted qualitative interviews with 28 policy actors to seek their views on the health system dynamics, how they sustain pharmaceutical incentivisation and their effect on the quality of care. Our analysis revealed four interlinked factors operating at different levels and how they collectively contribute to pharmaceutical incentivisation. In addition to influences such as the increasing family needs and peers’ financial success, sometimes GPs may naturally be inclined to maximise incomes by engaging in pharmaceutical incentivisation. On other hand, the pharmaceutical market dynamics that involve that competition underpinned by a profit-maximisation mindset enable pharmaceutical companies to meet GPs’ desires/needs in return for prescribing their products. Inadequate monitoring and health regulations may further permit the pharmaceutical industry and GPs to sustain the incentive-driven relationship. Our findings have important implications for potential health reforms such as introducing regulatory controls, and appropriate monitoring and regulation of the private health sector, required to address pharmaceutical incentivisation to GPs.
展开▼
机译:在巴基斯坦,通过对全科医生 (GP) 进行经济激励的药品营销是一个研究不足的卫生系统问题。药物激励被认为正在扭曲全科医生的处方行为,这可能会损害患者的健康和福祉。我们借鉴生态系统理论中概述的概念框架来确定与巴基斯坦 GP 的药物激励相关的多个因素。我们对 28 位政策参与者进行了定性访谈,以寻求他们对卫生系统动态、它们如何维持药物激励及其对护理质量的影响的看法。我们的分析揭示了在不同层面起作用的四个相互关联的因素,以及它们如何共同促进药物激励。除了家庭需求增加和同龄人财务成功等影响外,有时全科医生可能自然而然地倾向于通过参与药物激励措施来最大化收入。另一方面,以利润最大化心态为基础的涉及竞争的制药市场动态使制药公司能够满足 GP 的愿望/需求,以换取开他们的产品处方。监测和卫生法规不足可能会进一步允许制药行业和 GP 维持激励驱动的关系。我们的研究结果对潜在的健康改革具有重要意义,例如引入监管控制,以及对私营卫生部门进行适当的监测和监管,以解决对全科医生的药物激励问题。
展开▼